First-in-human study of the novel fibroblast activation protein-targeted 4-1BB agonist RO7122290 in patients with advanced solid tumors
- Mariana Bustamante1
- Eveline Nueesch1
- Chiahuey Ooi1
- Iakov I. Davydov1
- Roche Pharma Research and Early Development, Roche Innovation Center Basel; Basel, Switzerland
Would like to thank Nicolas Staedler who provided some of the codes used for analysis. We also would like to thank Alexandra-Cristina Nica who was involved in early stages of the analysis.